Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model

Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 ((177)Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT with (177)Lu labeled anti-human CD20 camelid single domain antibodies (sdAb) in a B16-melanoma model transfected...

Descripción completa

Detalles Bibliográficos
Autores principales: Ertveldt, Thomas, De Beck, Lien, De Ridder, Kirsten, Locy, Hanne, de Mey, Wout, Goyvaerts, Cleo, Lecocq, Quentin, Ceuppens, Hannelore, De Vlaeminck, Yannick, Awad, Robin Maximilian, Keyaerts, Marleen, Devoogdt, Nick, D'Huyvetter, Matthias, Breckpot, Karine, Krasniqi, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377759/
https://www.ncbi.nlm.nih.gov/pubmed/35499391
http://dx.doi.org/10.1158/1535-7163.MCT-21-0791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377759/
https://www.ncbi.nlm.nih.gov/pubmed/35499391
http://dx.doi.org/10.1158/1535-7163.MCT-21-0791

Ejemplares similares